Description of Tirzepatide
Tirzepatide is a dual receptor agonist targeting glucagon-like peptide-1 (GLP-1) receptor and insulinotropic polypeptide (GIP) receptor. Tirzepatide, developed by Lilly, is a chemically synthetic first-in-class peptide therapeutics for patients with type 2 diabetes, obesity, or overweight. It is licensed under the trade names Mounjaro and Zepbound.
Structural formula of tirzepatide
Yaohai Bio-Pharma offers tirzepatide as an active pharmaceutical ingredient (API)
| API, active substance |
Application |
| Tirzepatide, GIP/GLP dual agonist |
Tirzepatide API for injection formulation |
EN
AR
HR
CS
DA
NL
FI
FR
DE
EL
IT
JA
KO
NO
PL
PT
RO
RU
ES
SV
IW
ID
LV
LT
SR
SK
SL
UK
VI
ET
HU
TH
TR
FA
AF
MS
BE
MK
UR
BN
